About TRODELVY 180mg Injection
TRODELVY 180mg Injection is a medication used in the treatment of certain types of cancer. It is an antibody-drug conjugate (ADC) that combines a monoclonal antibody with a chemotherapy drug. The antibody in TRODELVY 180mg Injection targets a protein called Trop-2, which is often found in higher amounts on the surface of some cancer cells, particularly breast and urothelial cancer cells. The attached chemotherapy drug (SN-38) is released inside the cancer cells, which can help to destroy the cancer.
The dosage of TRODELVY 180mg Injection can vary depending on the specific cancer type, the patient’s weight, and other factors. The 180MG injection you mentioned likely refers to the dose of sacituzumab govitecan in the vial or syringe.
TRODELVY 180mg Injection is typically administered intravenously by a healthcare provider, and the dosing regimen would be determined by the prescribing oncologist based on the individual patient’s condition and needs.
It’s important to note that TRODELVY 180mg Injection is used for specific cancer indications, so its use and dosage should be carefully monitored and prescribed by a qualified medical professional. If you or someone you know is prescribed TRODELVY 180mg Injection, it’s essential to follow your healthcare provider’s instructions and ask them any questions you may have about the medication and its administration.
Uses Of TRODELVY 180mg Injection
- Metastatic triple-negative breast cancer (TNBC)
- Metastatic urothelial cancer
Benefits Of TRODELVY 180mg Injection
In Metastatic triple-negative breast cancer (TNBC)
TRODELVY 180mg Injection is indicated for the treatment of adult patients with metastatic TNBC who have received at least two prior therapies for metastatic disease. Triple-negative breast cancer is a type of breast cancer that lacks estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression. It can be a challenging subtype of breast cancer to treat, and TRODELVY 180mg Injection is used when other treatments have failed.
In Metastatic urothelial cancer
TRODELVY 180mg Injection is also used for the treatment of adult patients with locally advanced or metastatic urothelial cancer (bladder cancer) who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. Urothelial cancer is a type of cancer that can affect the bladder, ureters, or renal pelvis.
TRODELVY 180mg Injection works by delivering a chemotherapy drug specifically to cancer cells that express the Trop-2 protein. The monoclonal antibody component of TRODELVY 180mg Injection binds to Trop-2 on the cancer cell surface, allowing the attached chemotherapy drug to be released into the cancer cells, where it can cause cell death.
The use of TRODELVY 180mg Injection and its specific dosage will be determined by a healthcare provider based on the patient’s medical history, type and stage of cancer, and other individual factors. It’s essential for patients to discuss their treatment options and potential side effects with their healthcare team to make informed decisions about their care.
Side Effects Of TRODELVY 180mg Injection
TRODELVY 180mg Injection can cause various side effects, as is the case with most medications. It’s important for patients to be aware of these potential side effects and discuss them with their healthcare provider. The severity and frequency of side effects can vary from person to person.
Common side effects of TRODELVY
- Nausea and Vomiting
- Decreased Appetite
- Hair Loss
- Liver Enzyme Abnormalities
- Infusion Reactions
When using TRODELVY 180mg Injection for the treatment of cancer, it’s important to take certain precautions to ensure the safe and effective use of the medication.
Here are some precautions to consider:
- Medical Supervision
- Patient Monitoring
- Infection Risk
- Fertility and Pregnancy
- Liver Function
- Infusion Reactions
- Pre-existing Conditions
- Other Medications
- Driving and Operating Machinery